Chemistry:Sofpironium bromide
 | |
| Clinical data | |
|---|---|
| Trade names | Ecclock |
| Other names | BBI 4000 |
| Routes of administration | Topical gel |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H32BrNO5 |
| Molar mass | 470.404 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sofpironium bromide (trade name Ecclock; development code BBI-4000) is a drug used to treat hyperhidrosis (excessive sweating). It was approved in Japan in 2020 as a 5% gel for the treament of primary axillary hyperhidrosis (PAH).[1][2][3]
Mechanism of action
Sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands.[3] It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide,[4][5] meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.
History
Sofpironium bromide was discovered at Bodor Laboratories by Nicholas Bodor and licensed to Botanix SB, a subsidiary of Botanix Pharmaceuticals. This license was previously owned by Fresh Tracks Therapeutics, which was then sold to Botanix in 2022, exclusively in the field of hyperhidrosis, with all other uses having been retained by Bodor Laboratories. Additional sublicenses were executed with Kaken Pharmaceutical and Dong Wha Pharmaceutical.
References
- ↑ "Sofpironium Bromide: First Approval". Drugs 80 (18): 1981–1986. December 2020. doi:10.1007/s40265-020-01438-1. PMID 33236266.
- ↑ "Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis". Expert Opinion on Investigational Drugs 30 (5): 479–482. May 2021. doi:10.1080/13543784.2021.1900114. PMID 33691553.
- ↑ 3.0 3.1 "A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis". The Journal of Dermatology 48 (3): 279–288. March 2021. doi:10.1111/1346-8138.15668. PMID 33410265.
- ↑ "Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics". Pharmaceutical Research 20 (10): 1681–9. October 2003. doi:10.1023/a:1026160023030. PMID 14620526.
- ↑ "Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate". J. Pharm. Pharmacol. 57 (11): 1427–35. November 2005. doi:10.1211/jpp.57.11.0008. PMID 16259775.
 |  |
